SERCA 2a gene therapy - Celladon Corporation

Drug Profile

SERCA 2a gene therapy - Celladon Corporation

Alternative Names: AAV1/SERCA2a; Congestive heart failure gene therapy; MYDICAR; SERCA2a gene therapy

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator Celladon; Targeted Genetics
  • Developer Celladon; Eiger BioPharmaceuticals, Inc.
  • Class Gene therapies; Heart failure therapies
  • Mechanism of Action Adenosine triphosphatase stimulants; Gene transference; Sarcoplasmic reticulum calcium-transporting ATPase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Heart failure
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Heart failure; Pulmonary arterial hypertension; Renal failure
  • Discontinued Urinary incontinence

Most Recent Events

  • 22 Mar 2016 Celladon has merged with Eiger BioPharmaceuticals and the combined company is now called Eiger BioPharmaceuticals, Inc.
  • 23 Feb 2016 Celladon teminates a phase II trial for Heart failure (in patients with LVAD) in United Kingdom (NCT00534703)
  • 01 Feb 2016 Assistance Publique - Hôpitaux de Paris and Celladon terminates the phase II AGENT-HF trial in Heart failure in France (NCT01966887)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top